Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary bypass that is a mainstay of therapy in neonatal and pediatric patients with life threatening respiratory and/or cardiac failure. Historically, the use of ECMO in adults has been limited, but recent reports and technological advances have increased utilization and interest in this technology in adult patients with severe respiratory failure. As ECMO is considered in this critically ill population, patient selection, indications, contraindications, comorbidities, and pre-ECMO support are all important considerations. Once the decision is made to cannulate a patient for ECMO, meticulous multiorgan-system management is required, with a priority being placed on lung rest and minimization of ventilator-induced lung injury. Close monitoring is also necessary for complications, some of which are related to ECMO and others secondary to the patient's underlying degree of illness. Despite the risks, reports demonstrate survival > 70% in some circumstances for patients requiring ECMO for refractory respiratory failure. As the utilization of ECMO in adult patients with respiratory failure continues to expand, ongoing discussion and investigation are needed to determine whether ECMO should remain a "rescue" therapy or if earlier ECMO may be beneficial as a lung-protective strategy.
Introduction
Extracorporeal membrane oxygenation (ECMO) is an important therapeutic strategy that was developed and first used to support an adult patient with refractory respiratory failure over 40 years ago. 1 Since introduction, ECMO has become a mainstay in the management of neonatal and pediatric patients with refractory respiratory and/or cardiac failure secondary to a wide range of diagnoses, in-cluding meconium aspiration, pulmonary hypertension, pneumonia, myocarditis, cardiomyopathy, sepsis, and ARDS. [2] [3] [4] [5] [6] [7] Despite widespread use in neonates and children, implementation of ECMO in the adult population has traditionally been limited, 8 but recent evidence suggests that ECMO may positively impact survival in adult patients with refractory respiratory failure. [9] [10] [11] [12] [13] [14] [15] [16] Recent reports, along with considerable advances in technology, 17,18 including advanced design double-lumen cannula, "respiratory dialysis," and pumpless veno-arterial extracorporeal gas support devices, have led to steadily increasing utilization of ECMO in adult patients. 8, [19] [20] [21] [22] [23] [24] [25] Implementation of an adult ECMO program presents unique challenges related to patient selection, including age, weight, comorbid conditions, and degree of organ failure, which necessitate that both the risks and benefits associated with the decision to employ ECMO be carefully considered in each individual patient. While general guidelines are available to guide practitioners, ultimately, individualization and consideration of the specific clinical circumstances are important elements of patient selection and management. 26, 27 This comprehensive review will examine the current data supporting the use of ECMO in adults as well as discuss patient selection parameters, complications, and benefits and risks of implementation of this potentially life-saving technology.
ECMO Basics
ECMO is a form of cardiopulmonary life-support, which can be veno-venous (VV) or veno-arterial (VA). With VV ECMO, blood is drained from a central vein, passed through an oxygenator, and pumped back into the venous system of the patient (Fig. 1) . 28 When adequate gas exchange can be achieved and there is no substantial compromise of cardiac function, VV ECMO, due to its generally lower risk of complications, is often the preferred approach over VA ECMO. Most patients with respiratory failure refractory to conventional therapies can be supported with VV ECMO as a mechanism to augment gas exchange while avoiding toxic ventilator settings. With VV ECMO, the level of mechanical ventilatory support is decreased to mitigate ventilator-induced lung injury (VILI). While carbon dioxide clearance with this approach is easily achieved, oxygenation may be somewhat less efficient. Gas exchange goals should be set as appropriate for the specific clinical circumstance. As with mechanical ventilation and most other modes of respiratory support, VV ECMO does not represent a cure for any underlying disease process(es), but simply a means to "rest" the lungs and allow for disease resolution and recovery of pulmonary function.
In VA ECMO, blood is drained from a central vein in a manner analogous to VV ECMO, but is returned to the arterial system, generally via the carotid artery in neonates and children, and the femoral artery in adults (Fig. 2) . VA ECMO is essentially cardiopulmonary bypass for a period of days to weeks, and is extremely effective at both oxygenation and ventilation.
For adult respiratory failure, Ͼ 80% of ECMO cases reported to the Extracorporeal Life Support Organization (ELSO) since 1986 have been VV ECMO, and the percentage of patients supported with VV ECMO continues to increase each year. 8 We will focus in this paper on the use of VV ECMO in the adult population.
Evidence for ECMO in Adults
Shortly after ECMO was first described for adults in the early 1970s, 1 the National Institutes of Health conducted a multicenter randomized trial comparing ECMO with conventional ventilation in adult patients with severe respiratory failure. 29 In this trial, 90 patients across 9 centers were randomized to either conventional ventilation or VA ECMO. The mortality in both groups exceeded 90%. The authors of this study concluded that support with ECMO may temporarily improve gas exchange in patients with severe respiratory failure but did not impact hospital or long-term survival. 29 Over the next 10 years, case reports and small series in adults documented success using ECMO for refractory respiratory failure. [30] [31] [32] These data supported the notion that ECMO may have a role in a limited subset of critically ill adult patients, but there were no studies that demonstrated improvement in survival or other clinical outcomes in comparison to conventional mechanical ventilation. During this same time period in the late 1980s and early 1990s, neonatal ECMO became commonplace (Fig. 3) , with multiple studies demonstrating improved outcomes in these patients. 8, [33] [34] [35] [36] As successful use of ECMO in neonates continued to increase, a follow-up randomized trial was conducted to assess the impact of ECMO on adults with severe respiratory failure. 37 In this trial, Morris et al randomized 40 patients in a single center to either conventional ventilation or rescue with VV ECMO. This investigation demonstrated no significant outcome difference, with 42% survival in the conventional ventilation group, compared to 33% survival in the ECMO patients. 37 These data, in addition to the prior randomized trial that did not demonstrate superiority of ECMO in adult patients compared to conventional therapies, led to ECMO being used only sporadically in adults over the next 2 decades. Data reported to ELSO from 128 centers demonstrate that between 1986 and 2006 a mean of only 67 adult patients internationally were supported with ECMO annually for respiratory failure, compared to a mean of 1,207 neonatal and pediatric patients each year 36 (Fig. 4) .
The Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) trial, a multicenter randomized trial, was published in 2009. 14 In this investigation by Peek et al, 180 adults with acute refractory respiratory failure were randomized to ECMO or treatment with conventional mechanical ventilation. This randomized controlled trial demonstrated a significant improvement in 6 month disability-free survival in the ECMO group (63%), when compared to the conventional ventilation patients (47%) (P ϭ .03). 14 An important consideration in this study was that only 75% of the patients randomized and referred for ECMO were actually supported with ECMO, with the remaining 25% undergoing protocolized conventional mechanical ventilation at the ECMO referral center. While this percentage of ECMO referrals actually supported with ECMO is consistent with the 59 -86% reported by other centers, 16,38 some experts would suggest that this investigation is a study of referral to an experienced quaternary ECMO center rather than a comparison of ECMO with conventional ventilation. 39, 40 In addition, the conventional ventilation arm of the study was conducted at one of 92 different centers across England, without a specific ventilator management protocol. 14 Significantly fewer patients in the conventional ventilation group (70%) were treated with a "low-volume, low-pressure" ventilation strategy, when compared to the ECMO group (93%) (P Ͻ .001). 14 Despite the controversy associated with this study, these results likely contributed to the recent increased interest in ECMO worldwide as a therapeutic option in adult patients.
The results of the CESAR trial were published at a time when numerous reports were emerging that demonstrated successful utilization of ECMO to support critically ill adults infected with H1N1 influenza during the 2009 -2010 international pandemic. 9, 10, 12, 13, 15, 16, 38, [41] [42] [43] [44] Survival in these reports consistently ranged from 68 -83%, but most reports are single center experiences of Ͻ 15 patients. 9, 12, 13, 15, 16, 38, [41] [42] [43] [44] The largest series of 68 patients was published by the Australia and New Zealand ECMO investigators. 10 This observational investigation compared 68 patients supported with ECMO as a rescue for refractory respiratory failure to 133 mechanically ventilated patients with H1N1 not supported with ECMO. In this study, survival to ICU discharge in the ECMO patients was 77%, compared to 91% in the non-ECMO group (P ϭ .01). 10 Duration of ventilation and ICU stay were also longer in the ECMO group. These findings are not surprising, as ECMO was used in this study as a "rescue" therapy in those who failed more conventional management, and the survival rates are consistent with the multiple case and single center reports of ECMO utilization in adults during the H1N1 pandemic.
The combination of these H1N1 data and the publication of the CESAR trial has substantially renewed interest in the utilization of ECMO in adults with refractory respiratory failure over the past 5 years. In 2008 the number of adult respiratory failure patients reported to the ELSO registry increased to 190, with further increases to 437 in 2009, 418 in 2010, and 507 in 2011 36 (Fig. 5) . ECMO utilization for adult respiratory failure has exceeded pediatric respiratory cases annually for the past 2 years (see Fig. 4 ). Of note, the survival rates in adult patients supported with ECMO for respiratory failure in the past 5 years ranged from 53-61%, with 58% overall survival for adult respiratory failure ECMO patients in 2011. 8 
ECMO Patient Selection

ECMO Criteria
The increasing utilization of adult ECMO brings with it the challenge of patient selection and determination of ECMO candidacy. ECMO is primarily reserved for circumstances in which patients are refractory to escalating conventional therapies and have a "high" predicted mortality. The ELSO guidelines suggest that ECMO be considered in adult patients when predicted mortality exceeds 50%. 26, 27 In those with severe hypoxemic respiratory failure, a combination of P aO 2 /F IO 2 and Murray score are often utilized to determine the potential need for ECMO, with a P aO 2 /F IO 2 Ͻ 150 mm Hg on an F IO 2 of Ͼ 0.9 and a Murray score of 2-3 being associated with a predicted mortality of 50%. 26, 45 Other respiratory indications for ECMO in adults include respiratory acidosis refractory to conventional therapies and severe air leak.
As ECMO is being considered in an adult with progressive or refractory acute respiratory failure, the first question that must be answered for any potential ECMO patient is the reversibility of the underlying disease process. While lung injury and potential for pulmonary recovery is a crucial consideration, many other factors may impact a patient's potential for recovery. In adults, the risk generally increases with age, but this risk is likely related to comorbidities and other confounding factors rather than being directly age-related. Weight can also be a factor in patient selection, with morbid obesity contributing to potential difficulties with the cannulation procedure and/or achieving adequate ECMO blood flow. Limited data suggest that obesity may be an independent risk factor for ECMO mortality. 19, 46, 47 Comorbid conditions, degree of non-pulmonary organ dysfunction, and neurologic status are other patient specific considerations that impact ECMO candidacy and outcome. 26, [46] [47] [48] The decision to proceed with ECMO is also impacted by the duration of mechanical ventilation prior to cannulation. 26,48-50 VILI is a key contributor to morbidity and mortality in patients with severe respiratory failure, and avoidance of VILI is a key priority in the management of patients with respiratory failure. 51-54 One approach to minimize VILI is early initiation of ECMO to maintain adequate gas exchange while "resting" the lungs. Older data suggest that mortality is increased in patients who required mechanical ventilation for greater than approximately 7 days prior to cannulation, 26,49,50 but in the era of lungprotective ventilation, it is likely that the "acceptable" pre-ECMO duration of ventilation is longer. A recent review of the ELSO registry by Zabrocki et al demonstrated that between 1993 and 2007, survival in pediatric patients supported with ECMO remained stable between 56% and 61% when they were ventilated for Յ 14 days prior to cannulation. 48 In this study, survival fell to 38% in patients ventilated for Ͼ 14 days prior to ECMO cannulation. While duration of mechanical ventilation must be considered in the potential ECMO patient, current data would suggest that support with lung-protective mechanical ventilation for up to 2 weeks prior to initiation of ECMO may be acceptable.
Special Considerations
As ECMO is being considered as a support modality in patients with refractory respiratory failure, comorbidities are other important considerations. In both pediatrics and adults, the complexity of patients supported with ECMO is increasing. 48 , 55 Zabrocki et al reported that 47% of pediatric respiratory ECMO patients reported to ELSO in 2007 had a comorbid condition, compared to only 19% in 1997. 48 Despite this increased complexity, survival remained unchanged at 57%. 48 However, survival in pediatric patients with isolated respiratory failure without a comorbid condition increased significantly, from 57% to 72%, between 1993 and 2007. 48 This increased survival for patients with isolated pediatric respiratory failure is consistent with recent data in adolescents and young adults with minimal comorbidities supported with ECMO during the H1N1 pandemic. 9, 10, 12, 13, 15, 16, 38, [41] [42] [43] [44] Not surprisingly, Zabrocki et al also reported that the presence of comorbid conditions had a profound negative impact on overall survival in pediatric respiratory failure patients. 48 In the 3,213 children reviewed, renal failure was the most common comorbidity, present in 10% of patients prior to cannulation. Overall survival in the ECMO patients with preexisting renal failure was only 33%. 48 Other comorbidities were less common but also had a substantial impact on survival, as demonstrated by patients with malignancy, immunodeficiency, and history of solid organ transplantation having survival rates of 30%, 34%, and 16%, respectively. 48 As ECMO is being considered in the adult population, comorbid conditions and complications of critical illness are important considerations that may impact ECMO candidacy and anticipated outcome.
Another population of patients in which underlying comorbidity and organ dysfunction must be carefully considered are those with end-stage pulmonary disease awaiting lung transplantation. Outcomes for patients undergoing lung transplantation from ECMO traditionally have been poor, 56-62 but interest is growing in the utilization of "awake" ECMO as a bridge to lung transplantation 63-67 ( Fig. 6 ). Some authors suggest that the morbidity and mortality in patients bridged to lung transplantation with ECMO may be related to weakness and deconditioning, with rehabilitation pre-transplant on ECMO having the potential to improve outcomes. [63] [64] [65] [66] [67] [68] While there are a number of factors that must be considered when ECMO is being used as a bridge to lung transplantation, including institutional waiting lists, comorbid conditions, organ availability, and resource allocation, recent data would suggest that ECMO can be successfully implemented in select circumstances to bridge patients to lung transplantation. [63] [64] [65] [66] [67] [68] 
Techniques and Equipment
A given ECMO center may have single or multiple designs for ECMO circuits, depending on the resources available, institution preferences, and individual clinical circumstances. The basic components of a traditional ECMO circuit include the pump, oxygenator, cannula, circuit components, and various monitoring devices (Fig. 7) . For large pediatric and adult patients there has been movement toward simplification and miniaturization of ECMO circuits 69 (Fig. 8 ). These simplified circuits increase the portability of ECMO systems and require less intensive maintenance and monitoring. [67] [68] [69] [70] [71] In addition, a number of recent advances have occurred in cannula, oxygenator, and pump technology that may contribute to improved outcomes. 17, 28, [72] [73] [74] [75] [76] [77] ECMO cannulae design in adults has improved substantially. Introduction of a double lumen VV ECMO cannula (Avalon Laboratories, Rancho Domingo, California) that drains blood from both the superior and inferior vena cava and directs the return of blood directly across the tricuspid valve allows for single site percutaneous cannulation while minimizing recirculation through the ECMO system 64,67,78 ( Fig. 9 ). These cannulae allow for avoidance of femoral venous cannulation and thus increase patient mobility and lower complication rates. 64, 67, [78] [79] [80] These factors, along with the ease of use associated with a percutaneous double lumen cannula, likely have contributed to the upswing in adult ECMO utilization over the past few years. 8 ECMO pumps have traditionally involved a "roller-head" design in which 2 steel roller heads force blood forward through the tubing through sequential compression. However, the use of centrifugal pumps, which create flow via a magnet controlled, spinning motor, is increasing. In surveys of neonatal ECMO programs published by Lawson et al, use of roller head pumps decreased from 95% in 2002 to 53% in 2011. 81, 82 The impact of centrifugal pumps in comparison to roller head pumps is uncertain. Although advantages generally include quicker pump assembly, shorter cannulation time, and a lower priming volume, it should be noted that concerns have been raised regarding a potential increased risk for hemolysis and complications in neonates supported with centrifugal pumps. 83, 84 At this time, the impact of one pump type versus another in the adult population remains uncertain, and there is no specific recommendation or guideline available to direct selection of pumps for developing ECMO programs.
Oxygenator selection also has evolved with improved technology. In neonatal ECMO, silicone oxygenator use has fallen from 95% in 2002 to 25% in 2011, in association with an increase in application of polymethylpentine hollow fiber oxygenators. 81, 82 Hollow fiber oxygenators are associated with decreased inflammation, improved gas exchange, and decreased need for replacement (ie, last longer in clinical use) compared to the prior generation of oxygenators and are becoming standard in most ECMO centers. 17, 75, 77, 85 Additional technological advances beyond "traditional" systems have enhanced the ability to provide extracorporeal support to patients with severe respiratory failure. 22, 70, 71, [86] [87] [88] [89] [90] One important technological advance is the miniaturization of ECMO technology into a small selfcontained system with an oxygenator, a pump, and all of the components necessary to provide ECMO support. 70,71, 86 An example of this miniaturized technology is the CardioHelp system (Maquet, Wayne, New Jersey), which has been used to provide ECMO for transport, as a bridge to lung transplantation, and as a bridge to recovery for respiratory failure 70, 71, 86 (Fig. 10) .
Another important advance in technology is the ability to provide "pumpless" support to patients, using an arterial-venous system. 22, [87] [88] [89] [90] This system uses the patient's arterial pressure as the driving pressure through the membrane. The Novalung (Novalung, Heilbronn, Germany) is a device that has been successfully used as a bridge to both recovery and lung transplantation. 22, [87] [88] [89] [90] Additional investigation is warranted using these new devices to determine their optimal application, their impact on outcomes, and potential complications.
Complications
As discussed previously, the decision to support a patient with ECMO involves a number of crucial considerations. Patients in need of ECMO support have a high predicted mortality, and implementing an invasive therapy that requires central venous or arterial cannulation, systemic anticoagulation, and exposure to an extracorporeal bypass circuit involves substantial risk. While the data regarding complications for VV versus VA ECMO are not definitive, a number of studies in adults have demonstrated increased complication rates with VA ECMO. 79, 80, 91, 92 In addition, the potential impact of an embolic or thromboembolic event may be more catastrophic when it occurs in the arterial system.
The most common complication encountered in ECMO patients is bleeding. 8 Cannula and other surgical site bleeding are 2 of the most frequent hemorrhagic complications in patients reported to ELSO, occurring in approximately 17% and 16% of adult patients, respectively. 8 While cannula and surgical site bleeding can usually be readily controlled, bleeding in other locations can have severe consequences. Pulmonary hemorrhage occurs in approximately 8% of adult ECMO patients, with a 36% overall survival rate in these patients. 8 Intracranial bleeding is of particular concern, given the devastating consequences, with an overall 17% survival rate. Fortunately, only approximately 4% of adult ECMO patients develop central nervous system bleeding complications. 8 Other bleeding complications include gastrointestinal bleeding and disseminated intravascular coagulation, occurring in 5% and 4% of patients respectively.
Along with bleeding risk, there are a numerous other potential complications associated with supporting patients with refractory respiratory failure with ECMO (Table) . It is unclear whether complications are related specifically to ECMO as a support apparatus or to the degree of overall illness and organ dysfunction in these patients, but the etiology of the complications encountered during ECMO are likely multifactorial. For example, renal dysfunction is common, with 12% of adult respiratory ECMO patients developing a serum creatinine Ͼ 3.0 mg/dL, and 13% requiring dialysis. 8 In addition, over half of adult respiratory patients require inotropic support during ECMO for capillary leak and myocardial dysfunction. Also of note, despite the lung-protective approach employed in most circumstances, 13% of adult ECMO patients develop a pneumothorax requiring intervention. While support with ECMO may be a contributor to this multi-organ dysfunction, it is likely that degree of illness is a substantial contributor.
Infection is also relatively common, with culture proven infections occurring in approximately 20% of adult respiratory ECMO patients. 8 Interestingly, adult patients appear to have a significantly increased risk for infection while being supported with ECMO, when compared to pediatric and neonatal patients. 8, 93 Newer techniques that avoid the need for femoral cannulation may improve the risk for infection in adult ECMO patients, but there are currently no available data.
Finally, mechanical complications during ECMO are another important consideration. Clotting related to ECMO is a well reported mechanical complication, ranging from 2-12% for the various ECMO circuit components. 8 Other mechanical complications include circuit air, connection cracks, and failure of circuit components. Devastating complications, including tubing/circuit rupture, are rare, occurring in Ͻ 1.5% of patients, but a critical aspect of any ECMO program must be preparedness for potential complications.
Patient Management
As the utilization of ECMO in adult patients with life threatening respiratory failure continues to grow, an increasing emphasis will likely be placed on development of clear guidelines and standards. One important area of management in ECMO patients is mechanical ventilation strat- Additional areas of management in patients supported with ECMO are largely driven by underlying pathophysiology and disease process. Cardiovascular management includes vasoactive medications in more than half of respiratory adult VV ECMO patients, 8 but the decision to use these agents is largely determined by underlying degree of illness rather than ECMO support. Fluids, diuretics, antibiotics, sedation, and management of other organ systems and dysfunction are similarly dictated by the underlying clinical status of these critically ill patients.
Specific guidelines for clinical management of the ECMO patient are limited, but the ELSO published guidelines include considerations for patient selection, contraindications, and general management approaches. 26 Additionally, other publications are available to help guide practitioners in patient management and program development. 26, 69, [97] [98] [99] However, data are lacking on the efficacy of the various techniques and adjunctive therapies involved in the management of ECMO patients. Further investigation is needed to better clarify optimal approaches to support ECMO patients and potentially improve outcomes. Until then, clinical judgment and careful case by case consideration are needed to guide practitioners in decisions regarding supporting adults with life-threatening respiratory failure with ECMO.
Future Directions
With increasing ECMO experience and the potential for improved outcomes, some experts have begun to suggest early implementation of ECMO as a lung-protective strategy. 10,16,39,100 As VILI continues to be recognized as an important element of the morbidity and mortality of patients with acute respiratory failure, early initiation of ECMO represents an intriguing option to potentially improve outcomes and protect the lungs of these critically ill patients. Obviously, further data and investigation are needed to determine the impact of early implementation of ECMO on outcome, but, given recent data, clinical equipoise may exist for a large scale study to investigate this issue.
Summary
ECMO is a form of cardiopulmonary bypass utilized in select patients with a high expected mortality. While ECMO may be life-saving, the data to support the use of ECMO in adult patients are limited. A growing number of reports have been recently published that demonstrate survival rates Ͼ 70% in adult respiratory ECMO patients, but most studies do not have a comparison group and are not definitive. Despite limited data and lack of clear management guidelines, ECMO utilization in the adult population continues to rise, with survival rates remaining stable over time despite increasing complexity and more comorbid conditions. Bleeding remains the most common complication, but there are a number of other important potential complications, including renal dysfunction, infection, and mechanical problems.
Risks for complications may decrease as technology continues to improve, but data are limited and practitioners should carefully evaluate and investigate the various component options to further optimize the provision of ECMO. Although some general guidelines exist for the management of patients and the development of ECMO programs, practitioners are generally left to determine the appropriate approach for these most critically ill patients on a case by case basis. Finally, the difficult decision of the optimal timing of ECMO initiation remains unclear. Future investigation is needed to determine the overall impact of ECMO, and potentially earlier intervention with this support as a lung-protective strategy, on VILI and outcomes in adult patients with acute respiratory failure. MacIntyre: These VV ECMO systems are really good at clearing CO 2 -you can manage CO 2 almost entirely-but VV ECMO is borderline on oxygenation support, so you may not be able to get the ventilator off. Oxygenation is probably going to be a bigger problem than CO 2 .
Extracorporeal Life Support Organization (ELSO
Turner: I agree. With VV ECMO the lungs contribute to gas exchange, although to a variable degree, and many patients will have oxygen saturations in the mid-to-upper 80s. The amount you're able to decrease the ventilator depends on the balance between the patient's lungs and the ECMO flow characteristics. Our experience has been that, in most circumstances, VV ECMO patients do need the ventilator, but there have been reports of patients-especially patients being bridged to lung transplantation-who can tolerate tracheostomy collar or even extubation to NIV or room air.
Kallet:
We have a fellow at University of California San Francisco who trained at Michigan and had a lot of ECMO experience during the H1N1 outbreak. An interesting thing she pointed out is that the younger patients who were hyperdynamic didn't seem to do as well in terms of oxygenation. That's basically what Neil said about CO 2 not being a problem. They're hyperdynamic so the pump machine couldn't keep up with the oxygenation demands, but older people whose hearts couldn't handle the pulmonary vascular resistance from ARDS had a lower cardiac output and seemed to do much better on ECMO. Turner : We use that same model for our simplified VV ECMO systems. An RT is assigned to the ECMO patient and potentially other patients in the same pod, but there are other RTs assigned to manage the remainder of the ICU.
Kacmarek:
We have gotten to a point where now almost 25% of our RT staff is capable of manning the ECMO system. We're moving more into the management of cardiac patients. This year we will do about 35 patients, 30 of whom will be cardiac patients, with VA ECMO as the primary approach.
Turner: Our number of RTs trained to manage our ECMO systems also continues to grow, as do our number of annual ECMO patients. Overall, our patients are evenly distributed between cardiac and non-cardiac ECMO cases.
We are doing so many fewer adult respiratory ECMO cases: 2 to 4 per year at most. And we're pretty much the same with pediatric respiratory failure cases. For respiratory failure in neonates, pediatrics, and adults our numbers have been going way down.
Turner:
The data reported to ELSO show a downward trend in neonatal respiratory ECMO runs, but the annual number of pediatric respiratory ECMO runs has remained relatively stable following the increase in 2008-2009. 4 Most of the growth in respiratory ECMO over the past several years has been in adult patients.
MacIntyre: A few years ago there was a lot of interest in intracorporeal membrane oxygenation or ICMO, in which catheters are placed in the great vessels-the inferior vena cava-and you run O 2 through these tentacles. I think it was called the IVOX system, and there have been variations on it since. Where is that technology? Obviously, no pump is involved, and the membrane oxygenator is inside the body rather than outside.
Turner: There has been very little published on that in the past several years, but there are ongoing efforts to design smaller, simpler, and more efficient extracorporeal gas exchange devices.
Marini:
The capacity of those systems is considerably less than the present-day ECMO systems. And the catheters, as Neil alluded to, have also been improved. But the big problem with those is diffusion: getting O 2 to cross the diffusion barrier near the catheter is difficult, so for oxygenation they lack efficiency. On the CO 2 side they're a bit better because you can strip off about as much CO 2 as needed. Usually clearance is sufficient to bring the patient off the cusp of intolerance. I think they have a potential role, but certainly attention has diverted away from them.
Berra:
You showed that patients treated with ECMO after prolonged mechanical ventilation have worse outcomes. What causes the increased mortality, sepsis, or complications from ECMO?
Turner: Zabrocki 5 found that ECMO mortality was higher in pediatric patients mechanically ventilated for more than 14 days prior to ECMO cannulation. Overall survival in that study was 38% if the duration of pre-ECMO mechanical ventilation was greater than 14 days, in comparison to 56 -61% in patients ventilated for less than 14 days prior to ECMO. These data suggest that the decision to use ECMO should be made prior to 2 weeks of mechanical ventilation.
Schmidt:
That almost gets you into long-term ventilation: 3 weeks. If it's for 2 weeks on the ventilator, the mortality will increase. I think they're comparing apples and oranges; those are different patients. I'm not an ECMO believer, but I think it's unfair to ECMO to say that you shouldn't put somebody on it after 2 weeks of ventilation, because for someone on the ventilator for 3 weeks the mortality is also up at about 80% once they've stayed on the ventilator for 4 weeks. I think it's not a fair argument. It's not an argument against ECMO; it's an argument about ventilating too long.
Turner: An important issue here is that those data are from pediatric patients, and they also represent a change from prior studies 6, 7 that found that mortality increased after approximately one week of pre-ECMO mechanical ventilation. Based on these recent data from Zabrocki, 5 it would appear that the "safe" duration of pre-ECMO mechanical ventilation may be longer than it was in the past, potentially related to our lung-protective approaches.
Kacmarek: I've recently heard in a number of presentations that in Europe they're using VV ECMO to support patients with COPD and acute respiratory failure. I have not heard of anybody in the United States who is transitioning patients from NIV to VV ECMO. Is anybody doing that in the United States?
Turner: There seems to be growing interest in earlier cannulation of selected patients, and there are people in the United States who feel that ECMO should be used earlier, especially with the newer systems, simplification of cannulation, and decreased complication rates.
Kallet:
What is the infection rate, particularly from femoral-femoral cannulation? In my institution they're staying away from groin lines when-ever possible, because of infection concerns. What are the infection stats for ECMO?
Turner: In adult patients, cultureproven infection occurs in about 20% of respiratory ECMO patients. Interestingly, infection rates in adults are higher than in neonates and pediatrics, which may be related to the traditional femoral-femoral cannulation approach in adult patients. Culture-proven infection is approximately 18% in pediatrics, and only 6% in neonates. However, our local experience has been substantially lower infection rates in our patients. For whatever reason, adults are at higher risk of culture-proven infection during ECMO, and patients with these infections have a survival of 45%, compared to 57% in those without infections.
Gajic:
Have you had any experience with sterile inflammation, which can sometimes occur in these patients? We had a 20-year-old patient with acute interstitial pneumonia on ECMO who developed a leukemoid reaction, with a white blood cell count of 45,000, hyperinflammation, and fever, but he was clearly culture-negative and unlikely to be infectious. It happened toward the end of the need for ECMO support, and after the cannulas came out, 72 hours later the storm resolved.
Steroids were given and all of that. Any thoughts?
Turner: The timing of the inflammatory response you describe is interesting. You certainly can have an inflammatory response related to exposure to the bypass circuit and all the foreign materials with ECMO, but usually this response follows cannulation or a circuit or component change, within 24 to 48 hours. The severity and duration of inflammatory response is difficult to predict for any given patient. However, anecdotally, this inflammatory response appears to be less with some of the newer available circuit components.
